Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: Results from UKALL 2003

Rachael Hough, Clare Rowntree, Nick Goulden, Chris Mitchell, Anthony Moorman, Rachel Wade, Ajay Vora

Research output: Contribution to journalArticle

Abstract

Despite the substantial outcome improvements achieved in paediatric acute lymphoblastic leukaemia (ALL), survival in teenage and young adult (TYA) patients has remained inferior. We report the treatment outcomes and toxicity profiles observed in TYA patients treated on the UK paediatric ALL trial, UKALL2003. UKALL2003 was a multi-centre, prospective, randomized phase III trial, investigating treatment intensification or de-escalation according to minimal residual disease (MRD) kinetics at the end of induction. Of 3126 patients recruited to UKALL2003, 229 (7·3%) were aged 16-24 years. These patients were significantly more likely to have high risk MRD compared to 10-15 year olds (47·9% vs. 36·6%, P = 0·004). Nonetheless, 5-year event-free survival for the TYA cohort (aged 16-24 years) was 72·3% [95% confidence interval (CI): 66·2-78·4] overall and 92·6% (95% CI: 85·5-99·7) for MRD low risk patients. The risk of serious adverse events was higher in patients aged ≥10 years compared to those aged 9 or younger (P < 0·0001) and novel age-specific patterns of treatment-related toxicity were observed. TYA patients obtain excellent outcomes with a risk- and response-adapted paediatric chemotherapy protocol. Whilst those aged 10 years and older have excess toxicity compared with younger patients, the age association is specific to individual toxicities.

Original languageEnglish (US)
Pages (from-to)439-451
Number of pages13
JournalBritish Journal of Haematology
Volume172
Issue number3
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Young Adult
Pediatrics
Residual Neoplasm
Confidence Intervals
Disease-Free Survival
Drug Therapy
Survival
Therapeutics

Keywords

  • Acute lymphoblastic leukaemia
  • Chemotherapy
  • Efficacy
  • Teenage and young adult
  • Toxicity

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia : Results from UKALL 2003. / Hough, Rachael; Rowntree, Clare; Goulden, Nick; Mitchell, Chris; Moorman, Anthony; Wade, Rachel; Vora, Ajay.

In: British Journal of Haematology, Vol. 172, No. 3, 01.01.2016, p. 439-451.

Research output: Contribution to journalArticle

@article{30cbe9f2cdd642e48975ddf8e13a62c6,
title = "Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: Results from UKALL 2003",
abstract = "Despite the substantial outcome improvements achieved in paediatric acute lymphoblastic leukaemia (ALL), survival in teenage and young adult (TYA) patients has remained inferior. We report the treatment outcomes and toxicity profiles observed in TYA patients treated on the UK paediatric ALL trial, UKALL2003. UKALL2003 was a multi-centre, prospective, randomized phase III trial, investigating treatment intensification or de-escalation according to minimal residual disease (MRD) kinetics at the end of induction. Of 3126 patients recruited to UKALL2003, 229 (7·3{\%}) were aged 16-24 years. These patients were significantly more likely to have high risk MRD compared to 10-15 year olds (47·9{\%} vs. 36·6{\%}, P = 0·004). Nonetheless, 5-year event-free survival for the TYA cohort (aged 16-24 years) was 72·3{\%} [95{\%} confidence interval (CI): 66·2-78·4] overall and 92·6{\%} (95{\%} CI: 85·5-99·7) for MRD low risk patients. The risk of serious adverse events was higher in patients aged ≥10 years compared to those aged 9 or younger (P < 0·0001) and novel age-specific patterns of treatment-related toxicity were observed. TYA patients obtain excellent outcomes with a risk- and response-adapted paediatric chemotherapy protocol. Whilst those aged 10 years and older have excess toxicity compared with younger patients, the age association is specific to individual toxicities.",
keywords = "Acute lymphoblastic leukaemia, Chemotherapy, Efficacy, Teenage and young adult, Toxicity",
author = "Rachael Hough and Clare Rowntree and Nick Goulden and Chris Mitchell and Anthony Moorman and Rachel Wade and Ajay Vora",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/bjh.13847",
language = "English (US)",
volume = "172",
pages = "439--451",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia

T2 - Results from UKALL 2003

AU - Hough, Rachael

AU - Rowntree, Clare

AU - Goulden, Nick

AU - Mitchell, Chris

AU - Moorman, Anthony

AU - Wade, Rachel

AU - Vora, Ajay

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Despite the substantial outcome improvements achieved in paediatric acute lymphoblastic leukaemia (ALL), survival in teenage and young adult (TYA) patients has remained inferior. We report the treatment outcomes and toxicity profiles observed in TYA patients treated on the UK paediatric ALL trial, UKALL2003. UKALL2003 was a multi-centre, prospective, randomized phase III trial, investigating treatment intensification or de-escalation according to minimal residual disease (MRD) kinetics at the end of induction. Of 3126 patients recruited to UKALL2003, 229 (7·3%) were aged 16-24 years. These patients were significantly more likely to have high risk MRD compared to 10-15 year olds (47·9% vs. 36·6%, P = 0·004). Nonetheless, 5-year event-free survival for the TYA cohort (aged 16-24 years) was 72·3% [95% confidence interval (CI): 66·2-78·4] overall and 92·6% (95% CI: 85·5-99·7) for MRD low risk patients. The risk of serious adverse events was higher in patients aged ≥10 years compared to those aged 9 or younger (P < 0·0001) and novel age-specific patterns of treatment-related toxicity were observed. TYA patients obtain excellent outcomes with a risk- and response-adapted paediatric chemotherapy protocol. Whilst those aged 10 years and older have excess toxicity compared with younger patients, the age association is specific to individual toxicities.

AB - Despite the substantial outcome improvements achieved in paediatric acute lymphoblastic leukaemia (ALL), survival in teenage and young adult (TYA) patients has remained inferior. We report the treatment outcomes and toxicity profiles observed in TYA patients treated on the UK paediatric ALL trial, UKALL2003. UKALL2003 was a multi-centre, prospective, randomized phase III trial, investigating treatment intensification or de-escalation according to minimal residual disease (MRD) kinetics at the end of induction. Of 3126 patients recruited to UKALL2003, 229 (7·3%) were aged 16-24 years. These patients were significantly more likely to have high risk MRD compared to 10-15 year olds (47·9% vs. 36·6%, P = 0·004). Nonetheless, 5-year event-free survival for the TYA cohort (aged 16-24 years) was 72·3% [95% confidence interval (CI): 66·2-78·4] overall and 92·6% (95% CI: 85·5-99·7) for MRD low risk patients. The risk of serious adverse events was higher in patients aged ≥10 years compared to those aged 9 or younger (P < 0·0001) and novel age-specific patterns of treatment-related toxicity were observed. TYA patients obtain excellent outcomes with a risk- and response-adapted paediatric chemotherapy protocol. Whilst those aged 10 years and older have excess toxicity compared with younger patients, the age association is specific to individual toxicities.

KW - Acute lymphoblastic leukaemia

KW - Chemotherapy

KW - Efficacy

KW - Teenage and young adult

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84955685361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955685361&partnerID=8YFLogxK

U2 - 10.1111/bjh.13847

DO - 10.1111/bjh.13847

M3 - Article

C2 - 26683485

AN - SCOPUS:84955685361

VL - 172

SP - 439

EP - 451

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -